NCT02390297进行中(未招募)不适用
Long Term Follow-up for the Detection of Delayed Adverse Events in Recipients of CD4+ T Lymphocytes and/or CD34+ Hematopoietic Stem/Progenitor Cells Transduced With LVsh5/C46, a Dual Anti-HIV Gene Transfer Construct
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中(未招募)
- 入组人数
- 11
- 试验地点
- 2
- 主要终点
- Detection of delayed clinical or molecular adverse events related to Cal-1, or the associated delivery procedures
研究概览
简要总结
Long term safety follow-up of Cal-1 recipients
详细描述
Long Term Follow-up for the Detection of Delayed Adverse Events in Recipients of CD4+ T Lymphocytes and/or CD34+ Hematopoietic Stem/Progenitor Cells Transduced with LVsh5/C46 (Cal-1), a Dual Anti-HIV Gene Transfer Construct
研究设计
- 研究类型
- Observational
- 观察模型
- Other
- 时间视角
- Prospective
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signed informed consent
- •Previous treatment with the Cal-1 modified hematopoietic cellular products
排除标准
- •Inability to understand and provide informed consent
结局指标
主要结局
Detection of delayed clinical or molecular adverse events related to Cal-1, or the associated delivery procedures
时间窗: 15 years
次要结局
- Assessment of the long term survival and activity of Cal-1 modified hematopoietic cells through evaluation of Cal-1 marking and expression in peripheral blood(15 yars)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
不适用
Long-term Follow-up for Evaluating the Safety of CS20AT04 in Subject with Lupus NephritisLupus NephritisNCT04522505Corestemchemon, Inc.6
Unknown
1 期
Long-Term Follow-up Safety After DDS Implantation With/Without CDNF InfusionsMovement DisordersNeuro-Degenerative DiseaseNervous System DiseasesBrain DiseasesParkinson DiseaseNCT04228653Renishaw15
撤回
不适用
Long-Term Follow-up of the Safety and Efficacy of RCT-01 in Men and Women With Unilateral, Chronic Achilles TendinosisTendinosisTendinopathyNCT02655042RepliCel Life Sciences, Inc.
招募中
不适用
A Long-term Follow-up Study in Participants Who Received CS-101Beta-ThalassemiaNCT06479616Children's Hospital of Fudan University5
Enrolling By Invitation
不适用
A Follow-up Study to Evaluate the Long-term Safety and Efficacy in Participants Who Received CS-101 InjectionBeta-ThalassemiaNCT06717932CorrectSequence Therapeutics Co., Ltd8
